

Tuesday, April 18, 2006

COMPANY PRESS RELEASE

Transgenomic's Discovery Services Team Supports Study Linking Stem Cell Mutation to Blood Disorder and Development of Leukemia

Targeted Mutation Screening of Rare Cell Populations Provides Clues to Disease Mechanism and Suggests Possible Therapeutic Strategies

OMAHA, Neb., April 18, 2006 / -- Transgenomic, Inc. ([Nasdaq: TBIO](#)) announced today the publication of a study in which work performed by its Discovery Services team contributed to the finding that patients with a disorder called polycythemia vera (PV) have a mutation in the JAK2 gene in hematopoietic stem cells. These stem cells represent an early developmental stage in which the blood cells have not yet committed to a specialized function. The JAK2 mutation is likely to be associated with the excessive production of red blood cells in the bone marrow which is characteristic of PV.

Dr. Catriona H.M. Jamieson of the Moores Cancer Center at the University of California, San Diego, key contributing Stanford physician, Dr. Jason Gotlib, and lead scientist Dr. Irving Weissman, Director of the Institute for Stem Cell Biology and Regenerative Medicine and Comprehensive Cancer Center at the Stanford University School of Medicine, described this work in an article entitled, "The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation", which was published in the *Proceedings of the National Academy of Sciences* on April 18.

Dr. Jamieson commented on Transgenomic's contribution to this work. "The ability of Transgenomic Discovery Services' scientists to assess the mutational status of valuable clinical specimens that were available in limited quantities, and to do so in a timely manner, was critical to our success in this study."

Dr. Stan Lilleberg, Transgenomic's Director of Translational and Clinical Research and a co-author on the publication, stated, "We are pleased to have been involved in this ground-breaking work by Drs. Jamieson, Weissman and colleagues, and believe their findings will prove to be an important step in the development of targeted therapeutic strategies for treating polycythemia vera and related disorders, including some forms of leukemia."

About Transgenomic

Transgenomic is a global company that provides versatile and innovative products and services to the medical research and pharmaceutical markets. Transgenomic's WAVE Systems are specifically designed for use in genetic variation detection. They have broad applicability to genetic research and molecular diagnostics. The emerging pursuit of personalized medicine is driving the ongoing need to detect new, uncharacterized mutations and genetic polymorphisms. The high analytical sensitivity of the WAVE System makes it a uniquely enabling technology for the advancement of personalized medicine. To date there have been over one thousand systems installed in over 30 countries around the world. In addition to the sale of systems and consumables Transgenomic provides services to pharmaceutical and biopharmaceutical companies in preclinical and clinical development of targeted therapeutics. For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's Web site at www.transgenomic.com.

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and

estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the company's technology to contribute toward the continued advancement of translational research and the development of targeted cancer therapeutics. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For confirmation of release or further information, please contact:

Robert J. Pogulis, Ph.D.
Transgenomic Inc.
845-782-9617
rpogulis@transgenomic.com